Charles River Laboratories International Stock News

Charles River Laboratories International Inc''s (NYSE: CRL ) Q4 sales increased 14.4% Y/Y to $905.1 million , beating the consensus of $888.27 million. Acquisitions contributed 5.9% to consolidated fourth-quarter revenue growth. Organic revenue growth was 10.5%, driven by contributions from all three business segments. Adjusted EPS reached $2.49 higher than $2.39 posted a year ago and … Full story available on Benzinga.com

Charles River Laboratories International <> stock declined following its Q4 results, which beat analysts'' estimates, and reaffirming its 2022 Guidance.Q4 total revenue increased…

Shares of Charles River Laboratories (CRL) are struggling today even though the company posted Q4 2021 results that beat on the top and bottom lines.

Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.

Charles River Laboratories press release (CRL): Q4 Non-GAAP EPS of $2.49 beats by $0.06.Revenue of $905.05M (+14.4% Y/Y) beats by $16.78M.Reaffirms 2022 Guidance: Revenue growth 13.0%…

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results

Charles River (CRL) delivered earnings and revenue surprises of 2.89% and 1.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Charles River Laboratories (NYSE:CRL) is scheduled to announce Q4 earnings on Wednesday, February 16, before market open.The consensus EPS estimate is $2.43

Stocks with rising P/E often proves to be an intriguing investing idea.

Major players in the pyrogen testing market are Thermo Fisher Scientific Inc. , Merck KGaA, Charles River Laboratories Inc. , Lonza Group, Ellab A/S, Nelson Laboratories Inc. , Associates of Cape Cod Inc. Major players in the pyrogen testing market are Thermo Fisher Scientific Inc. , Merck KGaA, Charles River Laboratories Inc. , Lonza Group, Ellab A/S, Nelson Laboratories Inc. , Associates of Cape Cod Inc.

The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.

The "Physical, Engineering, And Life Sciences Global Market Report 2022" report has been added to ResearchAndMarkets.com''s offering. The global physical, engineering, and life sciences market is expected to grow from $391.44 billion in 2021 to $443.17 billion in 2022 at a compound annual growth rate (CAGR) of 13.2%. The market is expected to reach $687.28 billion in 2026 at a CAGR of 11.6%. Major players in the physical, engineering and life sciences market are IQVIA Holdings Inc, Battelle Memorial Institute, Syneos Health Inc, PRA Health Sciences Inc, Charles River Laboratories International Inc, PAREXEL International Corporation, Pharmaceutical Product Development LLC, Medpace Holdings Inc, Albany Molecular Research Inc and Hitachi High Technologies America Inc. Physical, Engineering, and Life Sciences establishments are engaged in conducting research and experimental development in physical, engineering, and life sciences such as agriculture, environmental, botany, electronics, chemistry, fisheries, forests, mathematics, veterinary and other allied subjects.

Charles River (CRL) could produce exceptional returns because of its solid growth attributes.

The whole Covid-19 pandemic has been a world-wide lesson in the need to be resourceful about the care of personal-life healthcare. Being prepared means the human race needs to anticipate how to deal w